Filtered By:
Condition: Thrombosis
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3595 results found since Jan 2013.
Outcome of cancer patients after atrial fibrillation ablation: Insights from the China-AF registry
CONCLUSIONS: This study suggests that catheter ablation could be feasible for rhythm control of AF patients with concomitant cancer.PMID:37736690 | DOI:10.1111/pace.14830
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Xiaodong Peng Liu He Nian Liu Yanfei Ruan Xin Zhao Xueyuan Guo Wei Wang Songnan Li Ribo Tang Caihua Sang Chenxi Jiang Ronghui Yu Deyong Long Xin Du Jianzeng Dong Changsheng Ma Source Type: research
Surgery As a Trigger for Incident Venous Thromboembolism: Results from a Population-Based Case-Crossover Study
Conclusions Major surgery was a trigger for VTE, but the association between surgery and VTE risk was in part explained by other VTE triggers often coexisting with surgery, particularly immobilization and infection.PMID:37736074 | PMC:PMC10511275 | DOI:10.1055/a-2159-9957
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Dana Meknas Sigrid K Br ækkan John-Bjarne Hansen V ânia M Morelli Source Type: research
Therapeutic benefits of prophetic medicine remedies in treating hematological diseases (A review article)
Am J Blood Res. 2023 Aug 15;13(4):130-142. eCollection 2023.ABSTRACTHematological disorders are common medical ailments constituting an important cause of morbidity and mortality worldwide, which may be managed efficiently using different prophetic medicine remedies as adjuvants to current therapeutics. Prophetic medicine includes the body of knowledge about medicine that has been derived from the deeds, customs (sunnah), ahadith (sayings), actions, and agreements of Prophet Muhammad, peace be upon him. This review article aims at exploring the magnitude of therapeutic benefits of prophetic medicine remedies as adjuvant tr...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Ghazi H Mogharbel Ahmad S Badawi Amal Yaseen Zaman Mehrevan M Abd Elmoniem Ibrahim M Abdel-Rahman Mariam Eid Alenazi Fareed Akbar Shah Mohamed Abdelnaem Aly Syed Nazar Imam Nusaybah Eid Alenazi Salah Mohamed El Sayed Source Type: research
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of individuals with lung and gastrointestinal cancers who were stratified by risk score according to thrombosis risk, risk-directed thromboprophylaxis reduced thromboembolism with a desirable number needed to treat, without safety concerns, and with reduced mortality. Individuals at low risk avoided unnecessary intervention. The findings suggest that biomarker-driven, risk-directed primary thromboprophylaxis is an appropriate approach in this population.TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000811202.PMID:37733336 | DOI:10.1001/jamaoncol.2023.3634
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Marliese Alexander Sam Harris Craig Underhill Javier Torres Sharad Sharma Nora Lee HuiLi Wong Richard Eek Michael Michael Jeanne Tie Jennifer Rogers Alexander G Heriot David Ball Michael MacManus Rory Wolfe Benjamin J Solomon Kate Burbury Source Type: research
Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium
CONCLUSION: TACE combination with lenvatinib plus sintilimab is effective in treating HCC with IVC and/or RA TT. The toxicities were manageable, with no unexpected safety signals. The baseline levels of serum PCT might be the predictive biomarkers for the triple combination therapy.PMID:37724186 | PMC:PMC10505388 | DOI:10.2147/JHC.S410967
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Shangkun Ning Xinge Li Xiangyu Ma Jibing Liu Xu Chang Source Type: research
In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery
CONCLUSIONS: RC, RN, and PN predisposes to a higher VTE and PE rates than RP. Moreover, among RC and RN patients with either VTE or PE, mortality is substantially higher than among their VTE or PE-free counterparts.PMID:37721691 | DOI:10.1245/s10434-023-14246-0
Source: Ann Oncol - September 18, 2023 Category: Cancer & Oncology Authors: Cristina Cano Garcia Stefano Tappero Mattia Luca Piccinelli Francesco Barletta Reha-Baris Incesu Simone Morra Lukas Scheipner Andrea Baudo Zhe Tian Benedikt Hoeh Francesco Chierigo Gabriele Sorce Fred Saad Shahrokh F Shariat Luca Carmignani Sascha Ahyai N Source Type: research
Correction: Anticoagulant Therapy for Cancer-Associated Thrombosis
Ann Intern Med. 2023 Sep 19. doi: 10.7326/L23-0345. Online ahead of print.NO ABSTRACTPMID:37722116 | DOI:10.7326/L23-0345
Source: Annals of Internal Medicine - September 18, 2023 Category: Internal Medicine Source Type: research
Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis
Cureus. 2023 Aug 14;15(8):e43447. doi: 10.7759/cureus.43447. eCollection 2023 Aug.ABSTRACTCancer patients' risk of developing venous thromboembolism (VTE) is four to seven times higher than the general population. Cancer-associated VTE (CA-VTE), is a leading cause of morbidity and mortality in cancer patients. Low Molecular Weight Heparin (LMWH) has historically been the mainstay treatment of CA-VTE; however, complications such as bleeding and recurrent VTE make it challenging to manage these patients. Recent randomized controlled trials (RCTs) have proven that direct oral anticoagulants (DOACs) are as efficacious as LMWHs...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Maryam F Baloch Adedimeji V Adepoju Vaibhavkumar Falki Mohsin Hajjaj Tatiana Habet Karina Habet Amtul Mahrosh Sumana Kundu Janvi Kataria Midhun Mathew Tugba Saka Mohammed Al-Tawil Source Type: research
Intracavitary cardiac metastasis of cervical squamous cell carcinoma with immune thrombocytopenia: a rare case report
We present the case of an adult patient diagnosed with cervical cancer and concurrent right ventricular cancer thrombus, accompanied by immune thrombocytopenia (ITP). The patient exhibited resistance to conventional ITP drugs, with suboptimal platelet response. However, upon achieving initial control of the tumor, the patient's platelet counts returned to normal. Notably, the addition of immune checkpoint inhibitors targeting PD-L1 resulted in effective tumor control, accompanied by sustained high platelet levels. Unfortunately, during subsequent anti-tumor therapy, the patient experienced a prolonged platelet rise time, r...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Ning Liu Deguan Lv Raydonna Rachel Schneider Hongyan Yang Mingyan Zhang Yanan Liu Meili Sun Source Type: research
Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores
This study aimed to (1) evaluate the efficacy of 4 existing cancer-specific VTE models in predicting VTE incidence among hospitalized mCRC patients, and (2) examine the influence of incorporating mCRC molecular subtypes into these models. We conducted an evaluation of 4 cancer-specific VTE models, including Khorana, Vienna CATS, Protecht, and CONKO in a dataset involving 1392 mCRC patients. To evaluate the predictive performance, we utilized receiver operating characteristic (ROC) curves for both the original models and the modified models that incorporated microsatellite instability status or KRAS/NRAS/BRAF mutations. Mor...
Source: Clinical Colorectal Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Li Qin Zhikun Liang Jingwen Xie Xiaoyan Li Source Type: research
Predicting Bleeding in Cancer-Associated Venous Thromboembolism: Another Milestone Achieved
Thromb Haemost. 2023 Sep 11. doi: 10.1055/s-0043-1775582. Online ahead of print.NO ABSTRACTPMID:37696302 | DOI:10.1055/s-0043-1775582
Source: Thrombosis and Haemostasis - September 11, 2023 Category: Hematology Authors: Vanessa Rold án Eva Soler-Espejo Francisco Marin Source Type: research
Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores
This study aimed to (1) evaluate the efficacy of 4 existing cancer-specific VTE models in predicting VTE incidence among hospitalized mCRC patients, and (2) examine the influence of incorporating mCRC molecular subtypes into these models. We conducted an evaluation of 4 cancer-specific VTE models, including Khorana, Vienna CATS, Protecht, and CONKO in a dataset involving 1392 mCRC patients. To evaluate the predictive performance, we utilized receiver operating characteristic (ROC) curves for both the original models and the modified models that incorporated microsatellite instability status or KRAS/NRAS/BRAF mutations. Mor...
Source: Clinical Colorectal Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Li Qin Zhikun Liang Jingwen Xie Xiaoyan Li Source Type: research
